IL287560B2 - mRNA formulation - Google Patents

mRNA formulation

Info

Publication number
IL287560B2
IL287560B2 IL287560A IL28756021A IL287560B2 IL 287560 B2 IL287560 B2 IL 287560B2 IL 287560 A IL287560 A IL 287560A IL 28756021 A IL28756021 A IL 28756021A IL 287560 B2 IL287560 B2 IL 287560B2
Authority
IL
Israel
Prior art keywords
mrna
pseudouridine
combination
anyone
thio
Prior art date
Application number
IL287560A
Other languages
English (en)
Hebrew (he)
Other versions
IL287560B1 (en
IL287560A (en
Inventor
Koker Stefaan De
Sanne Bevers
Peter Tomme
Original Assignee
Etherna Immunotherapies Nv
Univ Brussel Vrije
Koker Stefaan De
Sanne Bevers
Peter Tomme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Etherna Immunotherapies Nv, Univ Brussel Vrije, Koker Stefaan De, Sanne Bevers, Peter Tomme filed Critical Etherna Immunotherapies Nv
Publication of IL287560A publication Critical patent/IL287560A/en
Publication of IL287560B1 publication Critical patent/IL287560B1/en
Publication of IL287560B2 publication Critical patent/IL287560B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL287560A 2019-04-26 2020-04-24 mRNA formulation IL287560B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19171323 2019-04-26
PCT/EP2020/061477 WO2020216911A1 (en) 2019-04-26 2020-04-24 Mrna formulation

Publications (3)

Publication Number Publication Date
IL287560A IL287560A (en) 2021-12-01
IL287560B1 IL287560B1 (en) 2025-10-01
IL287560B2 true IL287560B2 (en) 2026-02-01

Family

ID=66290283

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287560A IL287560B2 (en) 2019-04-26 2020-04-24 mRNA formulation

Country Status (12)

Country Link
US (1) US20220362360A1 (enExample)
EP (1) EP3958893A1 (enExample)
JP (1) JP7650001B2 (enExample)
KR (1) KR20220023340A (enExample)
CN (1) CN114096272B (enExample)
AU (1) AU2020263948B2 (enExample)
BR (1) BR112021021262A2 (enExample)
CA (1) CA3138011A1 (enExample)
IL (1) IL287560B2 (enExample)
MX (1) MX2021013018A (enExample)
SG (1) SG11202111720TA (enExample)
WO (1) WO2020216911A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7496623B2 (ja) * 2019-01-04 2024-06-07 イーザアールエヌーエー イムノセラピーズ エンヴェー ｍＲＮＡワクチン
US20220143161A1 (en) * 2019-03-13 2022-05-12 Etherna Immunotherapies Nv Mrna vaccine
CN119701015A (zh) * 2023-09-26 2025-03-28 深圳瑞吉生物科技有限公司 一种细胞因子mRNA组合药物及其应用
CN121873266A (zh) * 2026-03-18 2026-04-17 北京悦康科创医药科技股份有限公司 一种增强肿瘤疫苗免疫原性的嵌合多肽及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180133311A1 (en) * 2007-09-14 2018-05-17 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2201100E (pt) * 2007-09-14 2016-06-03 Univ Brussel Vrije Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
EP3173474A1 (en) * 2007-09-14 2017-05-31 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2015071295A1 (en) 2013-11-12 2015-05-21 Vrije Universiteit Brussel Rna transcription vector and uses thereof
DK4276189T3 (da) * 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180133311A1 (en) * 2007-09-14 2018-05-17 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SRIRAM VAIDYANATHAN ET AL:, MAXIMIZING TRANSLATION OF CAS9 MRNA THERAPEUTICS BY SEQUENCE ENGINEERING AND CHEMICAL MODIFICATION, 13 May 2017 (2017-05-13) *

Also Published As

Publication number Publication date
BR112021021262A2 (pt) 2021-12-21
SG11202111720TA (en) 2021-11-29
AU2020263948B2 (en) 2026-06-25
CN114096272B (zh) 2024-08-06
EP3958893A1 (en) 2022-03-02
CN114096272A (zh) 2022-02-25
WO2020216911A1 (en) 2020-10-29
JP7650001B2 (ja) 2025-03-24
US20220362360A1 (en) 2022-11-17
AU2020263948A1 (en) 2021-12-23
MX2021013018A (es) 2022-03-11
CA3138011A1 (en) 2020-10-29
IL287560B1 (en) 2025-10-01
JP2022532038A (ja) 2022-07-13
KR20220023340A (ko) 2022-03-02
IL287560A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
JP7650001B2 (ja) ｍＲＮＡ製剤
JP6832904B2 (ja) 免疫療法のためのｒｎａ製剤
US20240325522A1 (en) Rna adsorbed onto lipid nano-emulsion particles and its formulations
JP2019515900A (ja) がんを処置するためのＴｏｌｌ様レセプター９アゴニストおよび腫瘍抗原を含む粒子の腫瘍内送達
KR20160055863A (ko) 면역 부활 활성을 갖는 올리고뉴클레오티드 함유 복합체 및 그 용도
CN117731769A (zh) 用于水痘带状疱疹病毒(vzv)的核酸疫苗
US12084703B2 (en) Synthetic self-amplifying mRNA molecules with secretion antigen and immunomodulator
CN119110847A (zh) 针对sars-cov-2变体的环状rna疫苗及其使用方法
CN115845043B (zh) 一种模板DNA分子及其在制备mRNA和疫苗中的应用
CN119654141A (zh) 脂质纳米颗粒的组合物
AU2022422532A1 (en) Immunostimulatory mrna compositions and uses thereof
JP2026512425A (ja) 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
Tang et al. Durable protective efficiency provide by mRNA vaccines require robust immune memory to antigens and weak immune memory to lipid nanoparticles
Kim et al. Dual-targeting mRNA cancer vaccines for simultaneous antigen presentation in dendritic and tumor cells
Cui et al. From design to clinical use: mRNA vaccines for infectious diseases and cancer
JP2023502925A (ja) 生体内遺伝子治療のためのポリマー封入ウイルスベクター
HK40068420A (en) Mrna formulation
CN121620389A (zh) 一种针对MICA/B靶点的mRNA肿瘤疫苗
Kim et al. Targeted suppression of type 1 interferon signaling during RNA delivery enhances vaccine-elicited immunity
HK40068420B (en) Mrna formulation
WO2025240477A1 (en) Methods and materials for enhancing delivery of nucleic acid to cells
WO2024020453A2 (en) Immune system modulators and uses thereof
Xia et al. Engineered bacteriophage nanoassemblies in vivo stabilize DC–T cell immune synapse for high-performance influenza vaccination
Pulakkat et al. Immunogene Therapy in Cancer
HK40113162A (en) Polynucleotide compositions and uses thereof